Hello, I want to use steroids at later ages in my life to improve health
Anyone have any interesting links containing health benefits towards, tendons, muscle, blood. Not really interested in bulking, how I see it, i'll use doses for up to two weeks which translates to one daily dose bodybuilders take... Thanks in advance;
Here's a few studys showing the health benefits of AAS, and negatives of low testosterone:
Aversa A, Bruzziches R, Francomano D, et al. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study. The journal of sexual medicine. 2010;7(10):3495-3503.
Bhasin, S., et al., Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab, 2010. 95(6): p. 2536-59.
Boyanov MA, Boneva Z, Christov VG. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. The aging male : the official journal of the International Society for the Study of the Aging Male. 2003;6(1):1-7.
Buvat, J., et al., Endocrine aspects of male sexual dysfunctions. J Sex Med, 2010. 7(4 Pt 2): p. 1627-56.
Buvat, J., et al., Testosterone deficiency in men: systematic review and standard operating procedures for diagnosis and treatment. J Sex Med, 2013. 10(1): p. 245-84.
Frederiksen L, Hojlund K, Hougaard DM, et al. Testosterone therapy increased muscle mass and lipid oxidation in aging men. Age (Dordr). 2012;34(1):145-156.
Hackett G, Cole N, Bhartia M, et al. Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. The journal of sexual medicine. 2013;10(6):1612-1627.
Haider A, Yassin A, Doros G, et al. Effects of Long-Term Testosterone Therapy on Patients with ?Diabesity?: Results of Observational Studies of Pooled Analyses in Obese Hypogonadal Men with Type 2 Diabetes. International journal of endocrinology. 2014:Article ID 683515.
Harkonen, K., et al., The polymorphic androgen receptor gene CAG repeat, pituitary-testicular function and andropaGloball symptoms in ageing men. Int J Androl, 2003. 26(3): p. 187-94.
Kalinchenko SY, Tishova YA, Mskhalaya GJ, et al. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. Clinical endocrinology. 2010;73(5):602-612.
Kapoor D, Goodwin E, Channer KS, et al. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. European journal of endocrinology / European Federation of Endocrine Societies. 2006;154(6):899-906.
Khaw, K.T., et al., Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation, 2007. 116(23): p. 2694-701.
Kvorning T, Christensen LL, Madsen K, et al. Mechanical muscle function and lean body mass during supervised strength training and testosterone therapy in aging men with low-normal testosterone levels. Journal of the American Geriatrics Society. 2013;61(6):957-962.
Malkin, C.J., et al., Low serum testosterone and increased mortality in men with coronary heart disease. Heart, 2010. 96(22): p. 1821-5.
Mesbah Oskui, P., et al., Testosterone and the cardiovascular system: a comprehensive review of the clinical literature. J Am Heart Assoc, 2013. 2(6): p. e000272.
Ohlsson, C., et al., High serum testosterone is associated with reduced risk of cardiovascular events in elderly men. The MrOS (Osteoporotic Fractures in Men) study in Sweden. J Am Coll Cardiol, 2011. 58(16): p. 1674-81.
Saad F, Aversa A, Isidori AM, et al. Onset of effects of testosterone treatment and time span until maximum effects are achieved. European journal of endocrinology / European Federation of Endocrine Societies. 2011;165(5):675-685.
Saad F, Haider A, Doros G, et al. Long-term treatment of hypogonadal men with testosterone produces substantial and sustained weight loss. Obesity (Silver Spring). 2013;21(10):1975-1981.
Saad F. Androgen therapy in men with testosterone deficiency: can testosterone reduce the risk of cardiovascular disease? Diabetes/metabolism research and reviews. 2012;28 Suppl 2:52-59.
Saad, F. and L. Gooren, The role of testosterone in the metabolic syndrome: a review. J Steroid Biochem Mol Biol, 2009. 114(1-2): p. 40-3.
Saad, F., Androgen therapy in men with testosterone deficiency: can testosterone reduce the risk of cardiovascular disease? Diabetes Metab Res Rev, 2012. 28 Suppl 2: p. 52-9.
Storer TW, Woodhouse L, Magliano L, et al. Changes in muscle mass, muscle strength, and power but not physical function are related to testosterone dose in healthy older men. Journal of the American Geriatrics Society. 2008;56(11):1991-1999.
Tajar, A., et al., Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study. J Clin Endocrinol Metab, 2010. 95(4): p. 1810-8.
Traish AM, Haider A, Doros G, et al. Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study. International journal of clinical practice. 2013.
Traish, A.M., Adverse health effects of testosterone deficiency (TD) in men. Steroids, 2014.
Traish, A.M., et al., Testosterone deficiency. Am J Med, 2011. 124(7): p. 578-87.
Traish, A.M., et al., The dark side of testosterone deficiency: I. Metabolic syndrome and erectile dysfunction. J Androl, 2009. 30(1): p. 10-22.
Traish, A.M., et al., The dark side of testosterone deficiency: III. Cardiovascular disease. J Androl, 2009. 30(5): p. 477-94.
Traish, A.M., F. Saad, and A. Guay, The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance. J Androl, 2009. 30(1): p. 23-32.
Traish, A.M., R. Abdou, and K.E. Kypreos, Androgen deficiency and atherosclerosis: The lipid link. Vascul Pharmacol, 2009. 51(5-6): p. 303-13.
Travison, T.G., et al., The relationship between libido and testosterone levels in aging men. J Clin Endocrinol Metab, 2006. 91(7): p. 2509-13.
Ullah, M.I., et al., Testosterone deficiency as a risk factor for cardiovascular disease. Horm Metab Res, 2011. 43(3): p. 153-64.
van den Beld, A., et al., Luteinizing hormone and different genetic variants, as indicators of frailty in healthy elderly men. J Clin Endocrinol Metab, 1999. 84(4): p. 1334-9.
Wang, C., et al., Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. J Androl, 2009. 30(1): p. 1-9.
Wu, F.C., et al., Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J Clin Endocrinol Metab, 2008. 93(7): p. 2737-45.
Wu, F.C., et al., Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med, 2010. 363(2): p. 123-35.
Yassin, A.A. and F. Saad, Improvement of sexual function in men with late-onset hypogonadism treated with testosterone only. J Sex Med, 2007. 4(2): p. 497-501.
Yassin, A.A. and F. Saad, Treatment of sexual dysfunction of hypogonadal patients with long-acting testosterone undecanoate (Nebido). World J Urol, 2006. 24(6): p. 639-44.
Yeap, B.B., A.B. Araujo, and G.A. Wittert, Do low testosterone levels contribute to ill-health during male ageing? Crit Rev Clin Lab Sci, 2012. 49(5-6): p. 168-82.
Baillargeon J, et al, Risk of Myocardial Infarction in Older Men Receiving Testosterone Therapy. Ann Pharmacother 1060028014539918, first published on July 2, 2014 as doi:10.1177/1060028014539918, 2014.